Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Gersbach
Duke University, Department: Biomedical Engineering
Should you be removed from our database? Contact us at [email protected]. Read more below.
Element Genomics, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Information is uploaded below
Engineering Targeted Epigenetic Modifiers for Precise Control of Gene Regulation
In addition to the sequence of the human genome, it has become clear that genome structure plays a critical role in health and disease. However, there are currently no tools to manipulate this genome structure in cells in a precise manner. As a result, it is not possible to reverse diseases or disorders related to genome structure or to perform experiments that increase our understanding of the role of genome structure in biological systems. In this proposal, we will develop tools for precisely modifying genome structure that will catalyze innovative advances in gene and cell therapy, drug development, and basic science.
Filed on December 21, 2016.
Tell us what you know about Charles Gersbach's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Charles Gersbach filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Gersbach | Duke University | Conflict of Interest | Editas Medicine | $200,000 - $249,999 |
| Charles Gersbach | Duke University | Conflict of Interest | Sarepta Therapeutics, Inc. | $100,000 - $149,999 |
| Charles Gersbach | Duke University | Conflict of Interest | Editas Medicine | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.